Phase II clinical trials are in progress for treatment of endometrial cancer, diffuse large B-cell lymphoma, cholangiocarcinoma, and non-Hodgkin lymphoma.<unk>  in combination with R-CHOP or R-B (rituximab and bendamustine) is in a phase III trial for relapsed indolent non-Hodgkin lymphoma (NHL). Two separate phase III trials are investigating the use of<unk>  in combination with rituximab for indolent NHL and the other using<unk>  alone in cases of rituximab-refractory indolent NHL. In a preclinical study,<unk>  was effective in inhibiting HER2+ breast cancer cells with acquired resistance to the HER2-inhibitors trastuzumab and/or lapatinib. This effect was increased when<unk>  was administered along with the aforementioned HER2-inhibitors. Consequently, treatments of<unk>  with trastuzumab are being clinically trialled in HER2-positive breast cancer patients.
Copanlisib
Elixir
Rolapitant
Mitapivat
Nyasol
Cobicistat
Lazaretto
Abametapir